Adagene Inc.
Business
Adagene Inc. is a platform-driven clinical-stage biotechnology company that discovers and develops novel antibody-based cancer immunotherapies. It designs and engineers therapeutics using its proprietary Dynamic Precision Library (DPL) and three technology platforms—NEObody, SAFEbody and POWERbody—advancing clinical candidates such as the masked anti‑CTLA‑4 ADG126 and a pipeline of preclinical and IND‑ready programs. Its business is organized around research and development, platform licensing and strategic collaborations with pharmaceutical partners and academic groups, and outsourced GMP manufacturing. Adagene conducts global clinical development and commercial programs across the U.S., China and Asia‑Pacific through direct trials, regional partnerships and out‑licensing arrangements.
Summary from filing dated 2025-03-24
Financials
Latest annual snapshot (FY2025, period end 2025-12-31). Full statement history unavailable for this entity.
| Revenue | $7.67M |
| Net income | $-17.61M |
| Total assets | $78.26M |
| Total liabilities | $26.36M |
| Stockholders' equity | $35.35M |
| Operating cash flow | $-15.66M |